That's quite realistic, IMO, if the STOP-HE trial is successful or (less likely, but possible) if OCRX inks a lucrative partnership to commercialize the IV and oral forms of OCR-002. Regards, Dew
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.